CHEOF
Cochlear Limited
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Strong sell
-62/100
Last price
90.45
▼ 0.41 (0.45%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
90.86
Day high
90.70
Day low
90.45
Volume
300
Market cap
$5.92B
P/E (TTM)
59.12
52W range
64.39 – 197.11
Trailing performance
Returnvs SPY
1W
-3.38%
-5.3%
1M
-10.49%
-12.0%
3M
+5.08%
+1.7%
6M
-29.59%
-44.6%
YTD
-46.34%
-60.3%
1Y
-51.11%
-66.8%
3Y
-44.59%
-126.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CHEOF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
378.00K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 1, 26 | Freudenstein (Richard John) Director (Non-Executive) |
BUY | 1.10K | $106.47K | Direct |
| Aug 24, 26 | Clarke (Caroline) Director (Non-Executive) |
BUY | 257 | $24.99K | Direct |
| Aug 24, 26 | Clarke (Caroline) Director (Non-Executive) |
BUY | 444 | $42.68K | Direct |
| Aug 24, 26 | Del Prado (Michael) Independent Non-Executive Director |
BUY | 412 | $28.50K | Direct |
| Aug 20, 26 | Clarke (Caroline) Director (Non-Executive) |
BUY | 431 | $41.85K | Direct |
| Aug 20, 26 | Daniell (Michael Grenfell) Director (Non-Executive) |
BUY | 386 | $37.27K | Direct |
| Aug 20, 26 | Del Prado (Michael) Independent Non-Executive Director |
BUY | 76 | $5.11K | Direct |
| Aug 19, 26 | Deans (Catriona Alison) Chairman of the Board |
BUY | 1.40K | $133.84K | Direct |
| Aug 19, 26 | McLoughlin (Christine Frances) Director (Non-Executive) |
OTHER | 2.40K | $236.78K | Direct |
| Aug 19, 26 | McLoughlin (Christine Frances) Director (Non-Executive) |
OTHER | 2.40K | $236.78K | Direct |
| Aug 19, 26 | Penrose (Karen Lee Collett) Independent Non-Executive Director |
BUY | 286 | $27.98K | Direct |
| Jun 30, 26 | Janssen (Jan) Chief Technology Officer |
— | 2.27K | — | Direct |
| Feb 19, 26 | Robinson (Bruce Gregory) Director (Non-Executive) |
BUY | 253 | $35.40K | Direct |
| Feb 18, 26 | Penrose (Karen Lee Collett) Independent Non-Executive Director |
BUY | 100 | $14.17K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
Clarke (Caroline) |
Director (Non-Executive) | 1.11K | Purchase |
Daniell (Michael Grenfell) |
Director (Non-Executive) | 2.00K | Purchase |
Deans (Catriona Alison) |
Chairman of the Board | 5.90K | Purchase |
Del Prado (Michael) |
Independent Non-Executive Director | 1.50K | Acquisition |
Freudenstein (Richard John) |
Director (Non-Executive) | 1.92K | Purchase |
Howitt (Diggory William) |
Chief Executive Officer | 64.99K | Sale |
Janssen (Jan) |
Chief Technology Officer | 7.30K | Other |
McLoughlin (Christine Frances) |
Director (Non-Executive) | 5.00K | Other |
Penrose (Karen Lee Collett) |
Independent Non-Executive Director | 1.81K | Purchase |
Robinson (Bruce Gregory) |
Director (Non-Executive) | 1.44K | Purchase |
Fundamentals
Market cap$5.92B
Enterprise value$5.94B
Revenue (TTM)$2.35B
Gross profit$1.66B
EBITDA$479.90M
Net income$147.30M
EPS (TTM)$1.53
Free cash flow$313.59M
Total cash$187.70M
Total debt$212.70M
Book value / share$18.50
Shares outstanding65.40M
Float65.14M
Short % of float—
Dividend yield2.01%
Beta (5Y)0.24
Valuation & profitability ratios
Trailing P/E59.12
Forward P/E—
PEG ratio—
Price / sales—
Price / book4.89
EV / revenue2.53
EV / EBITDA12.38
Gross margin70.69%
Operating margin14.33%
Profit margin6.27%
Return on equity7.98%
Return on assets9.71%
Debt / equity12.22
Current ratio2.15
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $2.35B | $2.34B | $2.24B | $1.94B | — | +0.2% |
| Operating revenue | $2.35B | $2.34B | $2.24B | $1.94B | — | +0.2% |
| Cost of revenue | $688.00M | $615.20M | $562.10M | $488.00M | — | +11.8% |
| Gross profit | $1.66B | $1.73B | $1.67B | $1.45B | — | -4.0% |
| Research & development | $323.20M | $291.50M | $277.00M | $244.90M | — | +10.9% |
| Selling, general & admin | $1.02B | $939.90M | $897.60M | $810.40M | — | +8.8% |
| Total operating expense | $1.45B | $1.32B | $1.26B | $1.14B | — | +9.7% |
| Operating income | $209.20M | $406.10M | $414.00M | $311.90M | — | -48.5% |
| Net interest income | -$3.00M | $700.00K | $9.80M | $7.10M | — | -528.6% |
| Pre-tax income | $213.90M | $518.50M | $484.80M | $396.60M | — | -58.7% |
| Tax provision | $66.60M | $129.60M | $128.00M | $96.00M | — | -48.6% |
| Net income | $147.30M | $388.90M | $356.80M | $300.60M | — | -62.1% |
| Net income to common | $147.30M | $388.90M | $356.80M | $300.60M | — | -62.1% |
| Basic EPS | — | 5.94 | 5.45 | 4.57 | 4.40 | — |
| Diluted EPS | — | 5.94 | 5.43 | 4.56 | 4.40 | — |
| EBIT | $227.10M | $529.50M | $494.00M | $406.00M | — | -57.1% |
| EBITDA | $331.80M | $619.90M | $578.90M | $486.90M | — | -46.5% |
| Basic shares | — | 65.44M | 65.54M | 65.76M | 65.77M | — |
| Diluted shares | — | 65.44M | 65.71M | 65.91M | 65.77M | — |
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $187.70M | $275.70M | $513.60M | $555.50M | — | -31.9% |
| Cash & short-term investments | $187.70M | $275.70M | $513.60M | $555.50M | — | -31.9% |
| Accounts receivable | $507.00M | $533.80M | $425.30M | $388.40M | — | -5.0% |
| Inventory | $491.30M | $499.40M | $391.60M | $311.50M | — | -1.6% |
| Total current assets | $1.30B | $1.42B | $1.45B | $1.36B | — | -8.2% |
| Property, plant & equipment | $525.00M | $536.20M | $517.20M | $447.20M | — | -2.1% |
| Goodwill & intangibles | $483.20M | $500.80M | $451.00M | $444.10M | — | -3.5% |
| Total assets | $2.60B | $2.83B | $2.75B | $2.57B | — | -7.9% |
| Total current liabilities | $604.50M | $602.30M | $631.50M | $578.00M | — | +0.4% |
| Current debt | — | — | — | — | $42.60M | — |
| Total debt | $212.70M | $235.70M | $243.70M | $201.80M | — | -9.8% |
| Total liabilities | $862.40M | $874.70M | $904.60M | $819.90M | — | -1.4% |
| Retained earnings | $645.70M | $777.30M | $667.90M | $555.40M | — | -16.9% |
| Shareholder equity | $1.74B | $1.95B | $1.84B | $1.75B | — | -10.8% |
| Working capital | $695.70M | $814.50M | $820.60M | $783.50M | — | -14.6% |
| Net tangible assets | $1.26B | $1.45B | $1.39B | $1.30B | — | -13.3% |
| Shares issued | 65.40M | 65.40M | 65.49M | 65.67M | — | +0.0% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Capital expenditure | -$90.70M | -$102.60M | -$89.80M | -$95.90M | +11.6% |
| Investing cash flow | -$104.50M | -$115.20M | -$105.70M | -$125.70M | +9.3% |
| Share buybacks | -$100.00K | -$28.30M | -$43.00M | -$29.60M | +99.6% |
| Dividends paid | -$281.20M | -$278.20M | -$245.70M | -$197.40M | -1.1% |
| Financing cash flow | -$344.00M | -$366.90M | -$323.80M | -$310.40M | +6.2% |
| Free cash flow | $277.30M | $135.00M | $299.00M | $266.50M | +105.4% |
| End cash position | $187.70M | $275.70M | $513.60M | $555.50M | -31.9% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2026-06-30 | 2025-06-30 | YoY |
|---|---|---|---|
| Cash & equivalents | $187.70M | $275.70M | -31.9% |
| Cash & short-term investments | $187.70M | $275.70M | -31.9% |
| Accounts receivable | $507.00M | $533.80M | -5.0% |
| Inventory | $491.30M | $499.40M | -1.6% |
| Total current assets | $1.30B | $1.42B | -8.2% |
| Property, plant & equipment | $525.00M | $536.20M | -2.1% |
| Goodwill & intangibles | $483.20M | $500.80M | -3.5% |
| Total assets | $2.60B | $2.83B | -7.9% |
| Total current liabilities | $604.50M | $602.30M | +0.4% |
| Total debt | $212.70M | $235.70M | -9.8% |
| Total liabilities | $862.40M | $874.70M | -1.4% |
| Retained earnings | $645.70M | $777.30M | -16.9% |
| Shareholder equity | $1.74B | $1.95B | -10.8% |
| Working capital | $695.70M | $814.50M | -14.6% |
| Net tangible assets | $1.26B | $1.45B | -13.3% |
| Shares issued | 65.40M | 65.40M | +0.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $2.37B | +1.0% |
| Next year | — | — | $2.50B | +5.6% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders0.58%
Held by institutions60.82%
Institutions holding268
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
92.73
-2.46% from price
SMA 20
94.25
-4.04% from price
SMA 50
93.18
-2.93% from price
SMA 100
84.73
+6.75% from price
SMA 200
112.91
-19.90% from price
EMA 12
92.74
-2.47% from price
EMA 26
93.39
-3.15% from price
EMA 50
92.25
-1.95% from price
RSI (14)
31.9
Neutral
MACD (12,26,9)
-0.64
Hist -0.64
ATR (14)
0.47
0.51% of price
Realised vol 30D
26.3%
Annualised
Bollinger upper
98.70
20, 2σ
Bollinger lower
89.80
20, 2σ
50 / 200 cross
Death
93.18 vs 112.91
Trend bias
Below 200
-19.90%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-0.40
Less volatile than market
Correlation to SPY
-0.08
Largely independent
Realised vol 30D
26.3%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-67.3%
Peak to trough
Max drawdown 5Y
-72.9%
Peak to trough
ATR 14
0.47
0.51% of price
Beta (reported)
0.24
5Y monthly, from filing
Dividends & splits
Forward rate$1.81 / yr
Forward yield2.01%
5-year avg yield1.42%
Payout ratio190.94%
Ex-dividend dateSep 21, 2026
Next pay dateApr 12, 2018
Last split—
Split date—
Headlines
Cochlear And 2 Australian Healthcare Stocks To Watch
Simply Wall St. · 7d ago
Cochlear Reaches More Than 1 Million Hours of Patient Experience Across Its Fully Implantable Hearing Technology Research Program
Business Wire · 10d ago
Cochlear Ltd's Dividend Analysis
GuruFocus.com · 16d ago
Lynas Rare Earths Stock And 2 High Quality Undervalued Picks
Simply Wall St. · 40d ago
Cash Flow Stocks With DCF Upside As Higher Bond Yields Test Valuations
Simply Wall St. · 41d ago
Health Care Roundup: Market Talk
The Wall Street Journal · 50d ago
Cochlear Ltd (CHEOF) (FY 2026) Earnings Call Highlights: Navigating Market Headwinds with Nexa ...
GuruFocus.com · 51d ago
Cochlear introduces the new Osia® 3 Sound Processor
PR Newswire · 87d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.